---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-088370"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T03:55:18.417613+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cara Therapeutics updates corporate presentation; cash $102M, pipeline catalysts outlined

## Summary
- Cash position $102M as of June 30, 2023, no debt, cash runway at least 12 months.
- KORSUVA injection launched in US (Apr 2022) and EU (Sep 2022); Japan approval expected 2H23.
- Oral difelikefalin in phase 3 for advanced CKD (KICK1/2, topline 2H24) and atopic dermatitis (KIND1/2, topline 1H25).
- Phase 2/3 for notalgia paresthetica (KOURAGE1) initiated 1Q23, topline 2H26.
- Partner CSL Vifor handles commercialization; Cara has no cash outlay for commercial costs.

## SEC filing metadata
- accession: 0001104659-23-088370
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465923088370/0001104659-23-088370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465923088370/tm2322717d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-088370
- JSON: https://secwatch.observer/filing/0001104659-23-088370.json
- Plain text: https://secwatch.observer/filing/0001104659-23-088370.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.